Ferrer, a privately-held Spanish pharmaceutical company today announces that it has licensed commercialisation rights for Ozenoxacin one per cent cream in the United States of America, Puerto Rico and the U.S. Virgin Islands to Medimetriks Pharmaceuticals Inc. Under the terms of the agreement Ferrer will be eligible to receive development milestones and revenues from sales in the Medimetriks territory.
Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
Provepharm¹s Japanese partner Daiichi Sankyo files an NDA to market the Methylene Blue injection medicinal product in Japan
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm’s Proveblue(R) Methylene Blue active substance.
This appointment makes the Montreal site attractive to North American clients and boosts CiToxLAB’s expertise in preclinical development and regulatory affairs.
TxCell announces the registration of its document de base with the French Autorité des marchés financiers (AMF) in the context of its planned IPO on the regulated market of Euronext Paris
TxCell, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces the filing of its document de base with the French Autorité des marchés financiers (the “AMF”) under number I.14-008 on March 13, 2014.
Adocia announces preliminary positive clinical results for its combination of long-acting insulin Glargine and fast-acting insulin analog Lispro, Biochaperone(R) Combo
Adocia’s BioChaperone Combo is the first product combining insulin Glargine with a fast-acting insulin analog
Phase I/II clinical trial demonstrates proof of concept in patients with type 1 diabetes, showing that BioChaperone Combo acts faster and longer than Humalog Mix
BANGKOK Feb. 25 2014 - UBM Asia is pleased to announce the launch of ASEANbeauty the only beauty trade event supported by the Thai Cosmetics Manufacturers Association. This is to be the premier international beauty trade show for South East Asia taking place in Thailand from 8-10 April 2015 at the Bangkok International Trade & Exhibition Centre.
WASHINGTON Feb. 26 2014 - U.S. News & World Report publisher of Best Hospitals and Best Children's Hospitals today released its Best Nursing Homes 2014 highlighting the top nursing homes in every state and nearly 100 major metropolitan areas.
NBE-Therapeutics Announces Successful Validation of its SMAC™-Technology for the Generation of Antibody Drug Conjugates (ADCs)
Basel, Switzerland, February 21, 2014 - NBE-Therapeutics (“NBE”) today announced that it has presented the successful validation of its enzymatic SMAC™-Technology for the generation of potent next-generation antibody drug conjugates (ADCs) at the international World ADC summit 2014 in Frankfurt, Germany, this week.
DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies
Strasbourg, France, February 4, 2014 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces it has entered into a multi-step collaboration with XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies.
Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
The agreement covers the creation and sale of rodent animal models, the sale of existing rodent animal models and sublicensing rights
Paris, France, February 4, 2014 – Cellectis (Alternext: ALCLS), the genome engineering specialist, and genOway (Alternext: ALGEN), the animal model specialist, today announce an exclusive agreement under which genOway becomes the exclusive provider of Cellectis’ homologous recombination technology for research applications in genetically modified rodents. Cellectis will remain the partner for any other applications, such as bioproduction and therapeutics. Financial details were not disclosed.
Page 1 of 60